Table 1.
Patient, tumor and treatment-related characteristics
| Characteristic | Findings |
|---|---|
| Age (y) | |
| Mean (range) | 60 (40–85) |
| 40–50 | 29 (19%) |
| 50–60 | 50 (33%) |
| >60 | 72 (48%) |
| Tumor Location | |
| UOQ | 54 (36%) |
| UIQ | 46 (30%) |
| LOQ | 30 (20%) |
| LIQ | 21 (14%) |
| Pathologic tumor stage | |
| Tis | 28 (19%) |
| T1mic | 1 (1%) |
| T1a | 19 (13%) |
| T1b | 52 (34%) |
| T1c | 38 (25%) |
| T2 | 13 (9%) |
| Sentinel lymph node biopsy (for patients with invasive cancer) | |
| Yes | 122 (99%) |
| No | 1 (1%) |
| Chemotherapy | |
| Yes | 30 (20%) |
| Anthracycline based chemotherapy | 26 (17%) |
| No | 121 (80%) |
| Hormonal therapy | |
| Yes | 116 (77%) |
| No | 35 (23%) |
| Method of catheter placement | |
| Open cavity | 13 (9%) |
| Closed cavity | 138 (91%) |
| Number of catheters | |
| Mean (range) | 21 (12–34) |
| V100 (cm3) | |
| Mean (range) | 246 (99.6–690) |
| V150 (cm3) | |
| Mean | 45.2 (19.1–129) |
| V200 (cm3) | |
| Mean | 16.1 (7–39.8) |
| DHI | |
| Mean | 0.808 (0.680–0.880) |
| IRAK | |
| Mean | 0.344 (0.199–0.659) |
| Toxicity | |
| Breast infection | 6 (4%) |
| Symptomatic fat necrosis | 19 (12.6%) |
Abbreviations: UOQ = upper outer quadrant; UIQ = upper inner quadrant; LOQ = lower outer quadrant; LIQ = lower inner quadrant; DHI = dose homogeneity index; IRAK = integrated reference air kerma